(HPQ) HP - Overview
Stock: Laptops, Desktops, Printers, 3D Printers, Workstations
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.38% |
| Yield on Cost 5y | 6.37% |
| Yield CAGR 5y | 8.83% |
| Payout Consistency | 92.7% |
| Payout Ratio | 37.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.9% |
| Relative Tail Risk | -3.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.11 |
| Alpha | -55.25 |
| Character TTM | |
|---|---|
| Beta | 1.226 |
| Beta Downside | 1.483 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.09% |
| CAGR/Max DD | -0.20 |
Description: HPQ HP December 17, 2025
HP Inc. (NYSE: HPQ) delivers personal computing, printing, 3D printing, hybrid-work, gaming and related technologies worldwide through three operating segments: Personal Systems (desktops, notebooks, workstations, thin clients, POS systems, displays, software and services), Printing (consumer and commercial printers, supplies, graphics, 3D-printing and personalization solutions) and Corporate Investments (business incubation and venture projects). The company, originally founded as Hewlett-Packard in 1939 and re-branded in 2015, serves consumers, SMBs and large enterprises from its Palo Alto headquarters.
Key recent metrics: FY 2024 Q2 revenue was $16.5 billion, with the Personal Systems segment contributing ~55 % and the Printing segment ~30 % of total sales; the Printing segment’s gross margin slipped to 22 % amid soft demand for consumables. Sector-wide, PC shipments are sensitive to corporate IT-capex cycles and the ongoing shift to hybrid work, while the printing market is being reshaped by cost-pressured enterprises adopting managed print services. HP’s 3D-printing business is growing at a double-digit CAGR, driven by increased adoption in aerospace and automotive prototyping.
For a deeper quantitative view of HP’s valuation and risk profile, you may find the ValueRay platform’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 2.53b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.21 > 1.0 |
| NWC/Revenue: -12.31% < 20% (prev -14.80%; Δ 2.49% < -1%) |
| CFO/TA 0.09 > 3% & CFO 3.70b > Net Income 2.53b |
| Net Debt (7.19b) to EBITDA (4.14b): 1.74 < 3 |
| Current Ratio: 0.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (948.0m) vs 12m ago -4.15% < -2% |
| Gross Margin: 20.60% > 18% (prev 0.22%; Δ 2038 % > 0.5%) |
| Asset Turnover: 135.4% > 50% (prev 134.2%; Δ 1.19% > 0%) |
| Interest Coverage Ratio: 5.81 > 6 (EBITDA TTM 4.14b / Interest Expense TTM 555.0m) |
Altman Z'' -0.76
| A: -0.16 (Total Current Assets 22.45b - Total Current Liabilities 29.26b) / Total Assets 41.77b |
| B: -0.05 (Retained Earnings -2.03b / Total Assets 41.77b) |
| C: 0.08 (EBIT TTM 3.22b / Avg Total Assets 40.84b) |
| D: -0.06 (Book Value of Equity -2.48b / Total Liabilities 42.12b) |
| Altman-Z'' Score: -0.76 = CCC |
Beneish M -2.98
| DSRI: 1.01 (Receivables 8.66b/8.32b, Revenue 55.30b/53.56b) |
| GMI: 1.07 (GM 20.60% / 22.07%) |
| AQI: 0.96 (AQ_t 0.36 / AQ_t-1 0.38) |
| SGI: 1.03 (Revenue 55.30b / 53.56b) |
| TATA: -0.03 (NI 2.53b - CFO 3.70b) / TA 41.77b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of HPQ shares?
Over the past week, the price has changed by +1.08%, over one month by -11.29%, over three months by -24.02% and over the past year by -37.05%.
Is HPQ a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 12
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the HPQ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25 | 27.3% |
| Analysts Target Price | 25 | 27.3% |
| ValueRay Target Price | 20.5 | 4.4% |
HPQ Fundamental Data Overview February 04, 2026
P/E Forward = 6.1996
P/S = 0.3349
P/EG = 1.3194
Revenue TTM = 55.30b USD
EBIT TTM = 3.22b USD
EBITDA TTM = 4.14b USD
Long Term Debt = 8.82b USD (from longTermDebt, last quarter)
Short Term Debt = 1.25b USD (from shortTermDebt, last quarter)
Debt = 10.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.19b USD (from netDebt column, last quarter)
Enterprise Value = 25.69b USD (18.52b + Debt 10.88b - CCE 3.71b)
Interest Coverage Ratio = 5.81 (Ebit TTM 3.22b / Interest Expense TTM 555.0m)
EV/FCF = 9.18x (Enterprise Value 25.69b / FCF TTM 2.80b)
FCF Yield = 10.90% (FCF TTM 2.80b / Enterprise Value 25.69b)
FCF Margin = 5.06% (FCF TTM 2.80b / Revenue TTM 55.30b)
Net Margin = 4.57% (Net Income TTM 2.53b / Revenue TTM 55.30b)
Gross Margin = 20.60% ((Revenue TTM 55.30b - Cost of Revenue TTM 43.90b) / Revenue TTM)
Gross Margin QoQ = 20.23% (prev 20.46%)
Tobins Q-Ratio = 0.62 (Enterprise Value 25.69b / Total Assets 41.77b)
Interest Expense / Debt = 1.15% (Interest Expense 125.0m / Debt 10.88b)
Taxrate = 4.68% (39.0m / 834.0m)
NOPAT = 3.07b (EBIT 3.22b * (1 - 4.68%))
Current Ratio = 0.77 (Total Current Assets 22.45b / Total Current Liabilities 29.26b)
Debt / Equity = -31.45 (negative equity) (Debt 10.88b / totalStockholderEquity, last quarter -346.0m)
Debt / EBITDA = 1.74 (Net Debt 7.19b / EBITDA 4.14b)
Debt / FCF = 2.57 (Net Debt 7.19b / FCF TTM 2.80b)
Total Stockholder Equity = -898.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.19% (Net Income 2.53b / Total Assets 41.77b)
RoE = -281.4% (negative equity) (Net Income TTM 2.53b / Total Stockholder Equity -898.8m)
RoCE = 40.68% (EBIT 3.22b / Capital Employed (Equity -898.8m + L.T.Debt 8.82b))
RoIC = 34.04% (NOPAT 3.07b / Invested Capital 9.03b)
WACC = 6.97% (E(18.52b)/V(29.40b) * Re(10.43%) + D(10.88b)/V(29.40b) * Rd(1.15%) * (1-Tc(0.05)))
Discount Rate = 10.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.83%
[DCF Debug] Terminal Value 80.55% ; FCFF base≈2.94b ; Y1≈2.64b ; Y5≈2.26b
Fair Price DCF = 47.17 (EV 50.50b - Net Debt 7.19b = Equity 43.30b / Shares 918.0m; r=6.97% [WACC]; 5y FCF grow -12.61% → 2.90% )
EPS Correlation: -58.55 | EPS CAGR: -4.38% | SUE: 0.30 | # QB: 0
Revenue Correlation: -52.94 | Revenue CAGR: -3.95% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.75 | Chg30d=-0.012 | Revisions Net=-3 | Analysts=12
EPS current Year (2026-10-31): EPS=3.10 | Chg30d=-0.018 | Revisions Net=-3 | Growth EPS=-0.5% | Growth Revenue=+1.3%
EPS next Year (2027-10-31): EPS=3.21 | Chg30d=-0.034 | Revisions Net=-3 | Growth EPS=+3.5% | Growth Revenue=+1.2%